within Pharmacolibrary.Drugs.ATC.N;

model N06AX62
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0012,
    adminDuration  = 600,
    adminMass      = 90 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.22,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX62</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bupropion and dextromethorphan combination is a novel investigational medication under study for the treatment of major depressive disorder and other neuropsychiatric conditions. Bupropion is an atypical antidepressant and dopamine-norepinephrine reuptake inhibitor, while dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist with potential antidepressant effects. The formulation is currently not broadly approved for therapeutic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects based on available data from individual components and limited public clinical data for the combination therapy.</p><h4>References</h4><ol><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993656/\">https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Dai, X, et al., &amp; Brantley, SJ (2021). Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers. <i>Clinical pharmacology in drug development</i> 10(8) 824–839. DOI:<a href=\"https://doi.org/10.1002/cpdd.961\">10.1002/cpdd.961</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34107166/\">https://pubmed.ncbi.nlm.nih.gov/34107166</a></p></li><li><p>Martinez, SE, et al., &amp; Court, MH (2024). Validation of a bupropion, dextromethorphan, and omeprazole cocktail for simultaneous phenotyping of cytochrome P450 2B11, 2D15, and 3A12 activities in dogs. <i>American journal of veterinary research</i> 85(7) –. DOI:<a href=\"https://doi.org/10.2460/ajvr.24.02.0049\">10.2460/ajvr.24.02.0049</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38718826/\">https://pubmed.ncbi.nlm.nih.gov/38718826</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX62;
